Lab Automation Advancing Research Workflows for Protein Biotherapeutics
The new Agilent 6560C Ion Mobility LC/Q-TOF features enhancements to the V-Works automation software suite, and new Assay MAP large capacity cartridges. These products are designed to improve the analysis of proteins and peptides to speed up the development of new protein-based therapeutics in biopharma.
Santa Clara/USA — As the market for protein biotherapeutics expands, pressure increases to improve the efficiency and efficacy of the development process. Researchers need more powerful, insightful instrumentation and software, as well as automation. There is also more focus on regulatory compliance, requiring organizations to maintain data integrity. The new Agilent 6560C Ion Mobility LC/Q-TOF enhancements address specific stages of the development workflow, from sample preparation to secure protocols, and software to complex protein structural analysis.
The new 6560C Ion Mobility Q-TOF adds new capabilities that enhance flexibility and performance over its predecessors for more precise measurements of large protein complexes such as biotherapeutic antibodies and large protein assemblies. Protein folding and structural analysis are now possible by CIU, and HRdm 2.0 postprocessing generates IM resolution of up to 250.
New features of the V-Works 14.1 automation software suite enhance support for 21 CFR Part 11 and Annex 11 with e-signatures and secure protocols for Assay MAP. V-Works 14.1 offers seamless adoption of automation and the Bravo platform into regulated environments to improve sample throughput, enhance reproducibility and reduce errors.
The Assay MAP large capacity cartridges extend the portfolio of available chemistries with the introduction of Protein A affinity purification cartridges and reversed-phase cartridges for antibody enrichment and peptide cleanup, respectively. These products enable automated sample preparation upstream of multiple critical quality analyses across the biotherapeutic development process.